Sinovant Sciences, a Shanghai-based biopharmaceutical company dedicated to bringing innovative medicines to China and advancing Chinese biopharmaceutical innovation abroad, unveiled its pipeline and leadership team at an event in Beijing.
Sinovant is backed by Roivant Sciences, a global healthcare company focused on reducing the time and cost of drug development, and CITICPE, a leading Chinese private equity firm. Roivant has supported Sinovant in assembling its pipeline and recruiting its senior leadership.
Sinovant began operations in 2017 and is led by co-founders Dr. Canwen Jiang and Dr. Xinan Chen. Sinovant has built a pipeline of 11 investigational biopharmaceutical products for Greater China and other Asian markets, including four therapies suitable for Phase 3 clinical trial application or registration in China. Sinovant’s investigational therapies address several of China’s greatest public health priorities, including liver cancer and drug-resistant bacterial infections.
Sinovant has also formed a partnership with China Liver Health, a leading Chinese public health nonprofit under the management of Ministry of Civil Affairs of China, to accelerate the availability of new treatments for liver disease and infectious diseases.